Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MDM2 |
Variant | amp |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | MDM2 amp indicates an increased number of copies of the MDM2 gene. However, the mechanism causing the increase is unspecified. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUS | 5 |
NCT06389799 | Phase II | Pemigatinib + Retifanlimab | A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) (PERELI) | Recruiting | SWE | NOR | 0 |
NCT06025747 | Phase I | Abemaciclib | Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma | Recruiting | USA | 0 |
NCT06578624 | Phase Ib/II | SA53-OS | Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | USA | 0 |
NCT04223596 | Phase II | Brigatinib | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK) | Active, not recruiting | ESP | 0 |
NCT05218499 | Phase II | BI 907828 Doxorubicin | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | Active, not recruiting | USA | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 5 |
NCT04776447 | Phase II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO) | Active, not recruiting | ESP | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT06058793 | Phase III | BI 907828 | Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma | Active, not recruiting | USA | ITA | GBR | CAN | BRA | BEL | AUS | ARG | 1 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Completed | USA | 0 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | Active, not recruiting | USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL | 2 |
NCT05012397 | Phase II | Milademetan | Milademetan in Advanced/Metastatic Solid Tumors | Terminated | USA | 0 |